Key Takeaways
- • Spire Healthcare accepted a £1.03 billion take-private offer at 250 pence per share, representing a 66% premium to the share price at the start of May when Toscafund first approached the board.
- • The bidding consortium comprises Toscafund (UK investment firm), THCP Advisory (UK private equity), and Ares (California-based investment manager), operating through acquisition vehicle Tulip UK Bidco.
- • Chief Executive Justin Ash and Chairman Sir Ian Cheshire will both depart; Sir David Sloman (former NHS trust leader) assumes interim CEO role, while Debbie White (ex-Co-op chair) becomes interim chair.
- • The consortium identified significant untapped value in Spire's freehold property assets, which it believes are undervalued in the public market share price, citing opportunity for strategic and financial flexibility under private ownership.
Summary
Spire Healthcare has agreed to a £1.03 billion take-private transaction following acceptance of an improved offer from a consortium of three investment firms. The deal, structured at 250 pence per share through acquisition vehicle Tulip UK Bidco, delivers a substantial 66% premium to Spire's trading price at the beginning of May, when Toscafund first signaled acquisition interest to the board.
The bidding consortium comprises three distinct investors: Toscafund, a British investment firm; THCP Advisory, a UK private equity specialist; and Ares, a California-based investment manager. The investor group's stated rationale focuses on unlocking value trapped in the London-listed private hospital operator's balance sheet. In particular, the bidco noted that "the value of the healthcare group's freehold property assets is not reflected in its share price" and argued that taking Spire private would "provide strategic and financial flexibility to unlock long-term stakeholder value."
The transaction triggers significant leadership changes at Spire. Justin Ash, the veteran chief executive who has led the group's evolution from a hospital-only business into an integrated healthcare company, will retire as the company enters what he described as "a new phase with strong foundations" under new ownership. Chairman Sir Ian Cheshire will also step down. Sir David Sloman, with extensive experience leading NHS trusts, will assume the interim chief executive position, while Debbie White, the former Co-op chair who stepped down from that role last month following a major cyberattack and workplace culture disputes, will serve as interim chair. White acknowledged Ash's contributions in transforming Spire's business model during the transition.
The takeover values Spire at £1.03 billion and removes the London-listed private hospital group from public markets, granting the investor consortium operational discretion to pursue strategic initiatives without quarterly earnings pressure or share price volatility constraints.
The bidding consortium comprises three distinct investors: Toscafund, a British investment firm; THCP Advisory, a UK private equity specialist; and Ares, a California-based investment manager. The investor group's stated rationale focuses on unlocking value trapped in the London-listed private hospital operator's balance sheet. In particular, the bidco noted that "the value of the healthcare group's freehold property assets is not reflected in its share price" and argued that taking Spire private would "provide strategic and financial flexibility to unlock long-term stakeholder value."
The transaction triggers significant leadership changes at Spire. Justin Ash, the veteran chief executive who has led the group's evolution from a hospital-only business into an integrated healthcare company, will retire as the company enters what he described as "a new phase with strong foundations" under new ownership. Chairman Sir Ian Cheshire will also step down. Sir David Sloman, with extensive experience leading NHS trusts, will assume the interim chief executive position, while Debbie White, the former Co-op chair who stepped down from that role last month following a major cyberattack and workplace culture disputes, will serve as interim chair. White acknowledged Ash's contributions in transforming Spire's business model during the transition.
The takeover values Spire at £1.03 billion and removes the London-listed private hospital group from public markets, granting the investor consortium operational discretion to pursue strategic initiatives without quarterly earnings pressure or share price volatility constraints.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.